PureTech Health plc 4

What Happened PureTech Health plc (reported as a 10% owner) converted multiple derivative securities of Seaport Therapeutics into common stock on May 4, 2026. The Form 4 shows disposal of 51,452,630 derivative/preferred shares (three conversion lots) and the acquisition of 16,382,534 common shares. All conversions reported a $0 cash price (i.e., no cash changed hands).

Key Details

• Transaction date: 2026-05-04; Form 4 filed 2026-05-06 (timely filing).
• Disposed (derivative/preferred) totals: 40,000,000; 8,421,052; 3,031,578 = 51,452,630.
• Acquired (common stock) totals: 12,736,014; 2,681,265; 965,255 = 16,382,534 common shares.
• Price / consideration: $0.00 for the disposed derivative securities (conversion, not a cash sale).
• Shares owned after transaction: Not specified in the information provided here (see the full Form 4 for total post-transaction beneficial ownership).
• Footnote F1: The Series A-1, A-2 and B Preferred were convertible into Common on a one-for-3.1407 basis and automatically converted on closing of the issuer’s IPO without payment. Footnote F2: PureTech LYT, Inc. is the record holder; PureTech Health plc is the ultimate owner and directs voting/disposition.

Context This is a conversion of derivative/preferred securities into common shares (corporate conversion event), not an open-market buy or sale. The reporting party is an institutional 10% owner (PureTech group), not an individual officer or director, so this filing reflects corporate ownership restructuring rather than a manager-level trade. Conversions at $0 are typical when preferred automatically convert into common under the terms noted in the footnote; they do not by themselves signal a buy/sell judgment by an insider.